Vivos Inc.'s Says Its Innovative Cancer Treatment Will Offer New Therapeutic Solution Using Proprietary Precision Radionuclide Therapy™

When discussing cancer treatment, chemotherapy is usually among the first solutions that come to mind. However, its familiarity does not necessarily speak to its efficacy, as the treatment also damages healthy cells while killing cancerous ones. While there are differing treatment approaches for cancer, Vivos Inc. RDGL is a medical device company taking a targeted approach to treating cancer with its patented Precision Radionuclide Therapy™ (PRnT™), which kills cancerous tumors while minimizing damage to healthy tissue.

What Is Precision Radionuclide Therapy™?

Precision Radionuclide Therapy™ is a proprietary treatment that uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area. As such, it delivers therapeutic radiation from within the tumor. PRnT™ reflects the science of radionuclide therapy, also known as nuclear medicine therapy, which involves the use of radioactive substances to treat diseases, most commonly cancer. The therapy utilizes radionuclides, which are radioactive isotopes attached to molecules that can specifically target cancer cells. This allows the radionuclides to deliver targeted radiation directly to the tumor or diseased area, minimizing damage to surrounding healthy tissue. The radioactive isotopes emit radiation that damages the DNA of the targeted cells, leading to cell death or a significant reduction in the cell’s ability to multiply.

PRnT™-Through IsoPet® 

Vivos Inc.'s leading PRnT™ product is IsoPet®, which the company says is a next-generation, safer and less invasive form of cancer treatment for animals. As this video shows, the cancer treatment is directly injected into solid tumors through a syringe. The benefits of this form of cancer treatment include quickness (Vivos Inc reports more than 90% of therapeutic radiation is delivered within 10 days of a single treatment, whereas others could take weeks to months), minimal side effects and greater safety to ‘healthy' organs. 

The global veterinary oncology market, valued at $1.18 billion in 2023, is projected to grow at a CAGR of 11.3% from 2024 to 2030. In the United States alone, approximately 6 million dogs and 6 million cats are diagnosed with cancer each year, alongside rising awareness of cancer in equines and exotic animals. Additionally, the larger global Animal Health Market reached $37.8 billion in 2023, and Vivos Inc. expects this to grow to $49.5 billion by 2032.

Margin therapy has enabled IsoPet® to target resected tumor margins, which reduces the risk of cancer recurrence. In 2025, the company is hoping to expand its network of certified clinics, which would enhance access to advanced cancer treatments for all animals including cats, dogs, horses and exotic animals. The company also reached a major milestone of treating its first exotic animal, a ferret, in September 2024. 

PRnT™-Based RadioGel® Treatment Reaches New Milestone On Path To Human Trials

Vivos Inc.’s RadioGel®, another PRnT™-based therapy aimed at cancer treatment in humans, is currently developing momentum on the way to FDA approval. The company aims to replicate the benefits it has seen on animal candidates – via the killing of tumors with minimal side effects and invasiveness – on humans, RadioGel®   is currently in the clinical trial phase in India, it has recently received encouraging words from the FDA. 

In December, the company announced its first human trial in India. As of February, Vivos reported that the first five patients demonstrated the safety of RadioGel® Precision Radionuclide Therapy™ by satisfying the criteria in the Clinical Study Plan, which included confirmation via PET imaging that the Y-90 remained at the point of injection and no adverse events reported since the initial treatment date.

"After years of dedicated effort, we are thrilled with these initial clinical trial results and optimistic about future findings. As the study progresses, we look forward to sharing additional updates. In parallel, we are advancing key growth initiatives to strengthen RadioGel®'s competitive position, and we will provide further updates on these technology and business developments in the coming weeks and months," shared CEO Dr. Michael Korenko.

Vivos Inc. – A  Leader In Precision Radionuclide Therap™

Vivos Inc.’s strategic endeavors in medical and veterinary oncology are indeed pushing the boundaries of healthcare innovation. Holding nearly 30 patents, including Precision Radionuclide Therapy™ and trademark protection for IsoPet®, RadioGel®, PrecisonGel™, Alpha-Gel®, Beta-Gel® and Gamma-Gel®, just to name a few, Vivos Inc has been hard at work securing its place as a leader in radionuclide therapy. 

Vivos Inc. is a fully reporting company that trades on the OTCQB Market under the symbol RDGL (www.otcmarkets.com/stock/RDGL/overview) With first in human trials underway in India, Breakthrough Device Designation from the FDA and significant growth of Isopet in the animal  health sector, Vivos Inc. is confident it is demonstrating its commitment to innovating cancer treatment and saving and improving lives worldwide. 

 Featured photo by Louis Reed on Unsplash.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.